At GoBroad Medical Institute of Hematology (Shanghai Center), we are dedicated to changing the journey of patients facing multiple myeloma diagnosis and treatment through advanced science, compassionate care, and a patient-first philosophy. As a certified bone marrow transplantation center and a member of the Shanghai Ruijin Hospital Blood Disease Medical Association, our facility integrates advanced diagnostics, innovative therapies, and multidisciplinary expertise to tackle this complex blood cancer. Led by Professor Wang Chun, a pioneer with over 30 years of experience in hematology, our team specializes in multiple myeloma diagnosis and treatment, offering tailored strategies that prioritize safety, efficacy, and long-term remission. With 32 laminar airflow transplant rooms, advanced laboratories, and seamless insurance services, we ensure accessible, world-class care for every patient.

Precision Diagnostics: The Foundation of Effective Myeloma Care

Accurate multiple myeloma diagnosis and treatment begins with unraveling the disease’s unique genetic and molecular profile. At GoBroad, we employ a comprehensive diagnostic toolkit—including flow cytometry, fluorescence in situ hybridization (FISH), and PCR testing—to identify critical markers like chromosomal abnormalities or elevated M proteins. For instance, FISH helps detect deletions in chromosome 17p, a high-risk feature guiding aggressive treatment plans. Our specialized labs also perform serum-free light chain assays and bone marrow biopsies to confirm myeloma staging, ensuring no detail is overlooked. This precision enables us to distinguish myeloma from related conditions like MGUS (monoclonal gammopathy of undetermined significance) or smoldering myeloma, allowing timely intervention. By anchoring multiple myeloma diagnosis and treatment in molecular insights, we tailor therapies to each patient’s disease biology, improving outcomes from the start.

Innovative Therapies: From Cellular Immunotherapy to Dual Transplants

For multiple myeloma diagnosis and treatment, GoBroad pioneers therapies that go beyond conventional approaches. Our protocols include adoptive cellular immunotherapy, such as CAR T-cell therapy, which reprograms a patient’s immune cells to target myeloma-specific antigens like BCMA. For relapsed or refractory cases, we combine CAR T with salvage chemotherapy to enhance response rates. Equally groundbreaking is our dual transplantation strategy—autologous stem cell transplant followed by allogeneic transplant—to deepen remission in high-risk patients. Professor Wang’s expertise ensures these complex procedures are optimized for safety, even in elderly patients or those with comorbidities. Post-transplant, we deploy personalized immunotherapy to maintain graft-versus-myeloma effects while minimizing graft-versus-host disease (GVHD). This integrative approach to multiple myeloma diagnosis and treatment has redefined survival expectations, offering hope where standard regimens fall short.

Global Access and Holistic Support for Myeloma Patients

Navigating multiple myeloma diagnosis and treatment should never be hindered by logistical barriers. At GoBroad, we simplify care for international patients through our dedicated service team, managing visa coordination, insurance claims (including real-time national cross-regional settlements), and multilingual support. A patient from abroad, for example, can undergo apheresis for stem cell collection, receive high-dose chemotherapy, and proceed with transplantation—all within our facility—supported by culturally sensitive care. Our holistic model extends beyond medical treatment: nutritionists, physical therapists, and mental health specialists collaborate to address fatigue, bone pain, and emotional challenges common in myeloma. Additionally, our partnership with Shanghai Ruijin Hospital ensures access to the latest clinical trials, such as novel proteasome inhibitors or monoclonal antibodies, keeping multiple myeloma diagnosis and treatment at the forefront of global innovation.

Conclusion

Choosing GoBroad Medical Institute of Hematology (Shanghai Center) means entrusting your multiple myeloma diagnosis and treatment to a team that blends scientific rigor with unwavering empathy. From molecular diagnostics and dual transplants to global patient support, we deliver care as unique as the individuals we serve. Whether confronting a new diagnosis or seeking alternatives for relapsed disease, our expertise—rooted in Professor Wang’s legacy and advanced infrastructure—offers a roadmap to resilience. Discover how GoBroad turns complexity into clarity, one myeloma patient at a time. Here, healing is not just about treating cancer—it’s about restoring life.